# High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma

> **NCT00544570** · NA · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** carmustine
- **DRUG:** cyclophosphamide
- **DRUG:** etoposide
- **DRUG:** melphalan
- **PROCEDURE:** autologous hematopoietic stem cell transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** radiation therapy
- **RADIATION:** total-body irradiation

## Key facts

- **NCT ID:** NCT00544570
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-04
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2010-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00544570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00544570, "High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00544570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*